Related Experiment Video

Updated: Aug 14, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Inhibitors of proteases as anticancer drugs

A Jedinak1, T Maliar

  • 1Istitute of Molecular Physiology and Genetics, Slovak Academy of Science, Bratislava 83334, Slovak Republic. andrejjedinak@orangemail.sk

Neoplasma
|May 6, 2005
PubMed

Insights

Proteolytic enzymes are crucial for cancer spread. Inhibiting these proteases, like matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA), with small molecules offers a promising anticancer and antimetastatic therapy strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Proteolytic enzymes are vital for physiological functions.
  • Dysregulation of proteolysis contributes to diseases, including cancer invasion and metastasis.
  • Proteolytic enzymes facilitate malignant cell passage and extracellular matrix invasion.

Purpose of the Study:

  • To review low molecular weight inhibitors targeting proteases involved in cancer metastasis.
  • To highlight the therapeutic potential of protease inhibition in anticancer strategies.

Main Methods:

  • Literature review focusing on inhibitors of matrix metalloproteinases (MMPs), urokinase plasminogen activator (uPA), and lysosomal proteases.
  • Analysis of studies investigating the effects of these inhibitors on tumor cell dissemination and growth.

Main Results:

  • Specific proteases like MMPs, cathepsins, plasmin, and uPA are implicated in tumor cell migration and invasion.
  • Natural and synthetic protease inhibitors demonstrate efficacy in preventing cancer cell spread and reducing tumor growth.
  • Low molecular weight inhibitors show promise as anticancer and antimetastatic agents.

Conclusions:

  • Inhibition of protease activity is a viable therapeutic strategy against cancer metastasis.
  • Targeting MMPs, uPA, and lysosomal proteases with small molecule inhibitors warrants further investigation for clinical application.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...